ATE302006T1 - Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen - Google Patents

Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen

Info

Publication number
ATE302006T1
ATE302006T1 AT00940504T AT00940504T ATE302006T1 AT E302006 T1 ATE302006 T1 AT E302006T1 AT 00940504 T AT00940504 T AT 00940504T AT 00940504 T AT00940504 T AT 00940504T AT E302006 T1 ATE302006 T1 AT E302006T1
Authority
AT
Austria
Prior art keywords
treatment
threomethylphenidate
hyperactivity disorder
therapeutic use
attention deficiency
Prior art date
Application number
AT00940504T
Other languages
German (de)
English (en)
Inventor
Elizabeth Janina Davidson
Original Assignee
Celltech Pharma Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Pharma Europ Ltd filed Critical Celltech Pharma Europ Ltd
Application granted granted Critical
Publication of ATE302006T1 publication Critical patent/ATE302006T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT00940504T 1999-06-09 2000-06-08 Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen ATE302006T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate
PCT/GB2000/002234 WO2000074680A1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder

Publications (1)

Publication Number Publication Date
ATE302006T1 true ATE302006T1 (de) 2005-09-15

Family

ID=10855048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940504T ATE302006T1 (de) 1999-06-09 2000-06-08 Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen

Country Status (9)

Country Link
EP (1) EP1185268B1 (https=)
JP (1) JP2003501387A (https=)
AT (1) ATE302006T1 (https=)
AU (1) AU766748B2 (https=)
CA (1) CA2376215A1 (https=)
DE (1) DE60022033T2 (https=)
ES (1) ES2243273T3 (https=)
GB (1) GB9913458D0 (https=)
WO (1) WO2000074680A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
NZ556456A (en) 2005-01-20 2010-12-24 Inst Molecular Medicine Inc Methylphenidate derivatives and uses of them
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
JP6983161B2 (ja) 2015-09-15 2021-12-17 プラクシス・バイオリサーチ・エルエルシー フェンカンファミンのプロドラッグ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) * 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
MX9805870A (https=) * 1996-01-22 1999-01-31
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate

Also Published As

Publication number Publication date
GB9913458D0 (en) 1999-08-11
DE60022033D1 (de) 2005-09-22
AU766748B2 (en) 2003-10-23
AU5543200A (en) 2000-12-28
EP1185268A1 (en) 2002-03-13
DE60022033T2 (de) 2006-03-30
WO2000074680A1 (en) 2000-12-14
CA2376215A1 (en) 2000-12-14
ES2243273T3 (es) 2005-12-01
EP1185268B1 (en) 2005-08-17
JP2003501387A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ATE215924T1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE322900T1 (de) Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE122005000011I1 (de) Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69814851D1 (de) Verwendung von levobupivacaine in gesichtschirugie
TR200000020T2 (tr) 5-HT3 ve 5-HT4 aracılı bozuklar için faydalı (+)-norsisaprit.
ATE302006T1 (de) Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
PT783495E (pt) Derivados de quinoxalina uteis em terapia
DE69829290D1 (de) Verwendung von alkanoylcarnitinderivaten zur behandlung von hyperaktivität mit aufmerksamkeitsstörungen
DE69918322D1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
AU2003270292A1 (en) Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
DE69816832D1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
DE60129599D1 (de) Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185268

Country of ref document: EP

REN Ceased due to non-payment of the annual fee